It has been reported in the literature that treatment of orthotopic mouse ovarian cancer tumors with an anti-TGFBI antibody reduced peritoneal tumor size, increased tumor monocytes, and activated β3-expressing unconventional T cells [85]. The gene discussed is TGFBI; the disease is ovarian cancer.